K Number
K190083
Manufacturer
Date Cleared
2019-05-03

(106 days)

Product Code
Regulation Number
886.4390
Reference & Predicate Devices
Predicate For
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The Norlase Leaf Photocoagulator is intended to be used in ophthalmic laser procedures including retinal and macular photocoagulation, iridotomy, and trabeculoplasty.

Device Description

The Norlase Leaf device consists of a laser unit, a wireless control unit and a foot switch. The laser unit must be attached to the Doctors own compatible slit lamp to work as a full system. The Norlase Leaf Device is controlled by the wireless control unit that allows the Doctor to set the desired parameters for treatment. A shrouded foot switch is connected to the laser unit to control the emission of laser light.

The Doctor will use the user supplied slit lamp to identify the area to be treated and after setting the appropriate parameters, will target the ophthalmic tissue utilizing a visible red aiming laser. The foot switch will be pressed by the Doctor to deliver therapeutic green laser light to the target tissue. A mechanically fixed eye safety filter is built into the Laser Unit to protect the Doctor from any stray or reflected green laser light travelling along the visual path of the slit lamp.

The Norlase Leaf device consists of the following modules:

  • -Laser unit + power supply + power cable
  • Foot switch + cable -
  • Control unit (Tablet computer with installed Software) + power supply + USB cable -

The wavelength of the treatment beam is centered around ~520 nm, and the maximum optical output power is 1.5W (to tissue). The laser is operated in continuous wave (CW) mode and electronically pulsing the laser output power to achieve durations from 50 usec to 1 second. Laser parameters are controlled by a Control Unit (tablet) User Interface that utilizes a touchscreen control to select or change a setting. Voice Control of selected parameters is an optional feature that can assist in the increment or selection of a parameter,

AI/ML Overview

The provided text describes the Norlase Leaf Photocoagulator, a medical device, and its acceptance criteria as part of a 510(k) premarket notification to the FDA. The study presented focuses on demonstrating substantial equivalence to a predicate device through verification and validation testing against recognized standards.

Here's an breakdown of the requested information based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The document states that "Every specification of the Leaf Photocoagulator device has been verified and validated according to the company's documented development and test procedures." It then lists the standards used for testing without explicitly detailing specific numerical acceptance criteria. However, the completion of these tests with "successful results" implies that the device met the requirements outlined within those standards.

Acceptance Criteria CategoryReported Device Performance
General Safety and Performance- Verified and validated according to Norlase ApS's documented development and test procedures.- Satisfactorily verified and validated all risk mitigations.- Demonstrated that technological differences from the predicate did not result in new issues of safety or efficacy.- Met design requirements and user needs.
Risk Management- Identified potential risks according to ISO 14971.- Analyzed risks with regard to risk/benefit category.- Implemented and tested mitigations as part of performance testing.
Electrical and Mechanical Safety- Bench testing for electrical and mechanical safety completed successfully in compliance with ISO 15004-2, IEC 60601-1+, IEC 60601-1-2, IEC 60601-2-22, IEC 60825-1, ANSI Z136-1, and ANSI Z136-3.
Laser Performance- Bench testing for laser performance completed successfully in compliance with ISO 15004-2, IEC 60601-1+, IEC 60601-1-2, IEC 60601-2-22, IEC 60825-1, ANSI Z136-1, and ANSI Z136-3.
Ophthalmic Device Specifics- Bench testing specific to ophthalmic devices completed successfully in compliance with ISO 15004-2.
Software Performance- Software testing completed successfully, including verification and validation in compliance with IEC 62304.- Included test cases related to off-the-shelf software and cybersecurity features.
Usability (Human Factors)- Human factors testing completed successfully to demonstrate usability in a simulated use environment when used by healthcare professionals, in compliance with IEC 62366-1.

2. Sample Size Used for the Test Set and the Data Provenance

The document does not specify a "sample size" in the context of patients or clinical data for testing the device's performance. It states that "Clinical data was not required for this type of device." The testing described is primarily laboratory-based (bench testing) and human factors testing in a simulated environment. Therefore, the "test set" consists of the device itself and its components, subjected to various engineering and usability tests, rather than a dataset of patient images or outcomes.

The "data provenance" is implied to be internal testing conducted by Norlase ApS, as described by "the company's documented development and test procedures." No specific country of origin or retrospective/prospective nature is applicable in the clinical sense, as no clinical data was used.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and the Qualifications of Those Experts

Not applicable. Since no clinical data was used and the testing consisted of bench testing and human factors in a simulated environment, there was no need for expert ground truthing of clinical cases. The "ground truth" for these types of tests would be the specifications and requirements defined by the standards and the device's design documentation.

4. Adjudication Method for the Test Set

Not applicable. As no clinical data requiring expert adjudication was used, there was no adjudication method like 2+1 or 3+1. The assessment of test results would be based on comparison against predefined technical specifications and standards (e.g., whether a certain parameter falls within a specified range, or whether a safety feature functions as intended).

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No. The document explicitly states: "Clinical data was not required for this type of device." Therefore, an MRMC comparative effectiveness study was not performed.

6. If a Standalone (i.e., Algorithm Only Without Human-in-the-Loop Performance) Was Done

This question seems to be more relevant to AI/CAD devices. The Norlase Leaf Photocoagulator is a direct treatment device, not an AI or diagnostic algorithm. Its performance is evaluated on its technical specifications and safety rather than algorithmic accuracy. The device's "standalone" performance would be its ability to emit laser light at specified parameters and its safety functions, which were evaluated through bench testing. Human factors testing, however, did involve human users (healthcare professionals) interacting with the device to assess usability, but this is distinct from "human-in-the-loop performance" in the context of an AI-assisted diagnostic task.

7. The Type of Ground Truth Used

The ground truth for this device's evaluation is primarily based on:

  • Technical specifications and design requirements: The device's ability to operate within specified ranges for wavelength, power output, exposure time, etc.
  • International and national standards: Compliance with standards like ISO 14971, ISO 15004-2, IEC 60601 series, IEC 60825-1, IEC 62304, IEC 62366-1, ANSI Z136-1, and ANSI Z136-3. These standards define acceptable performance and safety criteria.
  • Usability metrics: Outcomes from human factors testing demonstrating that the device can be used safely and effectively by healthcare professionals in a simulated environment.

8. The Sample Size for the Training Set

Not applicable. This is not an AI/machine learning device, so there is no training set as would be used for an algorithm.

9. How the Ground Truth for the Training Set Was Established

Not applicable, as there is no training set for this type of device.

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food & Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, with the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.

Mav 3, 2019

Norlase ApS % Sheila Pickering Consultant Sheila Pickering Consulting Group 2081 Longden Circle Los Altos, CA 94024

Re: K190083

Trade/Device Name: Leaf Photocoagulator Regulation Number: 21 CFR 886.4390 Regulation Name: Ophthalmic Laser Regulatory Class: Class II Product Code: HQF Dated: January 16, 2019 Received: February 04, 2019

Dear Sheila Pickering:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809 ): medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

for Malvina B. Eydelman, M.D. Director OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Indications for Use

FormAppr
09100120Exp
31, 2017See below.
510(k) Number (if known)K190083
-----------------------------------
Device NameNorlase Leaf Photocoagulator
-------------------------------------------

Indications for Use (Describe)

The Norlase Leaf Photocoagulator is intended to be used in ophthalmic laser procedures including retinal and macular photocoagulation, iridotomy, and trabeculoplasty.

Type of Use (Select one or both, as applicable)
☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

This section applies only to requirements of the Paperwork Reduction Act of 1995. DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number. "

{3}------------------------------------------------

510(k) Summary Prepared January 16, 2019

Sponsor:Norlase ApSBrydehusvej 302750 BallerupDenmark
Contact Person:Jan Forstberg
Telephone:+4593977472
Submission Date:January 16, 2019
Device Name:Leaf Photocoagulator
Common Name:Photocoagulator
Classification:
Regulatory Class:II
Review Category:Ophthalomology Photocoagulator21CFR 886.4390 (HQF)
Classification Panel:Ophthalmology

A. Legally Marketed Predicate Devices

The predicate device is the NIDEK Green Laser Photocoagulator GYC-500 ("NIDEK"). (K152603)

B. Device Description:

The Norlase Leaf device consists of a laser unit, a wireless control unit and a foot switch. The laser unit must be attached to the Doctors own compatible slit lamp to work as a full system. The Norlase Leaf Device is controlled by the wireless control unit that allows the Doctor to set the desired parameters for treatment. A shrouded foot switch is connected to the laser unit to control the emission of laser light.

The Doctor will use the user supplied slit lamp to identify the area to be treated and after setting the appropriate parameters, will target the ophthalmic tissue utilizing a visible red aiming laser. The foot switch will be pressed by the Doctor to deliver therapeutic green laser light to the target tissue. A mechanically fixed eye safety filter is built into the Laser Unit to protect the Doctor from any stray or reflected green laser light travelling along the visual path of the slit lamp.

The Norlase Leaf device consists of the following modules:

  • -Laser unit + power supply + power cable
  • Foot switch + cable -
  • Control unit (Tablet computer with installed Software) + power supply + USB cable -

{4}------------------------------------------------

The wavelength of the treatment beam is centered around ~520 nm, and the maximum optical output power is 1.5W (to tissue). The laser is operated in continuous wave (CW) mode and electronically pulsing the laser output power to achieve durations from 50 usec to 1 second. Laser parameters are controlled by a Control Unit (tablet) User Interface that utilizes a touchscreen control to select or change a setting. Voice Control of selected parameters is an optional feature that can assist in the increment or selection of a parameter,

C. Intended Use

The Leaf Photocoagulator is intended to be used in ophthalmic laser procedures including retinal and macular photocoagulation, iridotomy and trabeculoplasty.

Device NameNorlase LEAF green laserphotocoagulatorGreen Laser PhotocoagulatorGYC-500SubstantiallyEquivalent
ManufacturerNorlaseNidekN/A
510(k) number-K152603N/A
510(k) clearance date-05/02/2016N/A
Review panelOphthalmicOphthalmicYES
Product codeHQFHQFYES
Regulation number886.4390886.4390YES
Regulation descriptionOphthalmic laserOphthalmic laserYES
ClassificationIIIIYES
Indication for use andIntended useThe Norlase Leaf Photocoagulatoris intended to be used inophthalmic laser proceduresincluding retinal and macularphotocoagulation, iridotomy andtrabeculoplasty.The NIDEK Green LaserPhotocoagulator GYC-500 isintended to be used in ophthalmicsurgical procedures including retinaland macular photocoagulation,iridotomy and trabeculoplasty.YES
User interfaceManual and voice controlManualYES
ConnectivityWirelessHard wiredYES
Laser typeLaser diodeDiode-Pumped Solid-State laserYES
Wavelength520 nm532 nmYES
Laser modeContinuous waveContinuous waveYES
Power output50 to 1500 mW50 to 1700 mWYES
Exposure time(Duration time)0.05 ms to 1 s0.01 s to 3 sYES
Interval time50 ms to 3 s50 ms to 1 sYES
Cooling methodAir cooledAir cooledYES
Aiming beam:
TypeLaser diodeLaser diodeYES
Wavelength635 nm635 nmYES
Laser modeContinuous waveContinuous waveYES
Power output<1 mW (adjustable)<0.4 mW (adjustable)YES
Voltage100 to 240 Vac 50/60 Hz100 to 240 Vac 50/60 HzYES
Power consumption120 VA250 VAYES
Dimension253 (H) x 153 (W) x 43 (D) mm237 (W) x 318 (D) x 90 (H) mmYES
Weight~1.5 kg (excluding control unit,foot switch and power supply)6.2 kg (excluding the control box)YES

D. Substantial Equivalence

{5}------------------------------------------------

In summary based on the comparison of indications for use and technological characteristics of the subject device is substantially equivalent to the predicate. Based on the performance data provided in the submission these differences do not introduce new issues related to safety and efficacy.

E. Performance Data

Every specification of the Leaf Photocoagulator device has been verified and validated according to the company's documented development and test procedures. The verification and validation testing included testing to the following applicable standards:

ISO 14971Application of risk management to medical devices
ISO 15004-2Ophthalmic instruments - Fundamental requirements andtest methods - Part 1: Light hazard protection
IEC 60601-1+Medical electrical equipment- General requirements forbasic safety and essential performance
IEC 60601-1-2Electromagnetic disturbances
IEC 60601-2-22Medical electrical equipment - Part 2: Particularrequirements for the safety of diagnostic and therapeuticlaser equipment
IEC 60825-1Safety of laser products - Part 1: Equipment classification,and requirements [Including: Technical Corrigendum 1(2008), Interpretation Sheet 1 (2007), Interpretation Sheet 2(2007)]11
IEC 62304+Medical device software - Software life-cycle processes
IEC 62366-1Application of usability engineering to medical devices
ANSI Z136-1American National Standard for Safe Use of Lasers
ANSI Z136-3American National Standard for Safe Use of Lasers inHealth Care

Verification and validation testing were completed in accordance with the company's Design Control process in compliance with 21 CFR Part 820.30. Successful results for the following tests were included in the submission as performance data supporting substantial equivalence:

    1. Bench testing for electrical and mechanical safety in compliance with the laser standards cited above
    1. Bench testing for laser performance in compliance with the laser standards cited above
    1. Bench testing specific to ophthalmic devices in compliance with the standard cited above

{6}------------------------------------------------

    1. Software testing, consisted of verification and validation testing in compliance with ISO 62304, including test cases related to off the shelf software as well as cybersecurity features
    1. Human factors testing to demonstrate usability in a simulated use environment when used by health care professionals

Clinical data was not required for this type of device.

F. Conclusion

Potential risks were identified according to the ISO 14971 Standard. The risks were analyzed with regard to risk/benefit category and mitigations were implemented and tested as part of the performance testing described above. All risk mitigations were satisfactorily verified and validated. Where there were technological differences from the predicate, these were shown not to result in any new issues of safety or efficacy according to the performance data submitted.

Therefore, the Leaf Photocoagulator is substantially equivalent to the predicate device with regards to intended use and technological characteristics. Results of performance testing demonstrated that the device met the design requirements and as well as the user needs

§ 886.4390 Ophthalmic laser.

(a)
Identification. An ophthalmic laser is an AC-powered device intended to coagulate or cut tissue of the eye, orbit, or surrounding skin by a laser beam.(b)
Classification. Class II.